Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome
2017 ◽
Vol 52
(11)
◽
pp. 1530-1536
◽
2013 ◽
Vol 55
(5)
◽
pp. 1113-1118
◽
2016 ◽
Vol 58
(4)
◽
pp. 872-881
◽
2012 ◽
Vol 18
(2)
◽
pp. S348
◽
2020 ◽
Vol 99
(4)
◽
pp. 63-70